^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
D3S-002
i
Other names: D3S-002
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
D3 Bio
Drug class:
ERK2 inhibitor, ERK1 inhibitor
Related drugs:
5ms
Study of D3S-002 as Monotherapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations (clinicaltrials.gov)
P1, N=60, Active, not recruiting, D3 Bio (Wuxi) Co., Ltd | Recruiting --> Active, not recruiting
Enrollment closed
|
D3S-002
over2years
Study of D3S-002 as Monotherapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations (clinicaltrials.gov)
P1, N=60, Recruiting, D3 Bio (Wuxi) Co., Ltd | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
D3S-002
over2years
Study of D3S-002 as Monotherapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations (clinicaltrials.gov)
P1, N=60, Not yet recruiting, D3 Bio (Wuxi) Co., Ltd
New P1 trial • Metastases
|
D3S-002
Share via
